ALSO NOTED: Sirna soars on new study; FDA rejects Namenda bid; Immunogen inks new licensing deal; and much more...

> A new study published in Nature Biotechnology confirms that Sirna Therapeutics technology may well form the basis of a new class of drugs -- sending its stock up 50 percent. Story

> Citing conflicting trial data, the FDA has rejected Forest Laboratories' bid to market Namenda as a treatment for mild Alzheimer's. Report

> Shares of ImmunoGen were on the rise this morning after it announced a new licensing deal with Genentech for its cancer-fighting agents. Story

> GlaxoSmithKline, Europe's biggest drug maker, launched Phase III clinical trials of a treatment for AIDS made by Ono Pharmaceutical. The drug, called ONO-4128/873140, will be administered to HIV-positive patients who already have been treated with other AIDS drugs. Ono licenses the drug to GlaxoSmithKline, which is expanding its line-up of AIDS treatments. Story

> Adventrx's NNRTI drug shows in-vitro power against resistant HIV. Release

> Valeant Pharmaceuticals plans to start Phase III trials of Retigabine, its first-in-class epilepsy drug. Release

> Serologicials subsidiary Chemicon International has inked a deal to commercialize research products based on patented human embryonic stem (ES) cell technology developed by Wisconsin Alumni Research Foundation. Release

> 454 Life Sciences receives $11.5 million in milestone payments from Roche. Release

> ImClone profit climbs on sales of its Erbitux cancer drug. Story

And Finally... Mars chocolatiers are in talks with biotechs to develop medical applications for cocoa flavanols. Report

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.